skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

71 Total results for product and free and sample content found

Biomedtracker: 開発中医薬品をFDA承認確率で評価, Datamonitor...

Deconstructing the KRAS+ market opportunity

By Daniel Chancellor 06 Aug 2019

With arguably the standout data from the 2019 American Society for Clinical Oncology (ASCO) annual meeting, Amgen has become the first company to show that KRAS, beyond its role as an oncogene, is also a viable drug target

Topic biopharmaceutical drug-review

Datamonitor Healthcare: 医療用医薬品の市場調査レポート, Phar...

Opening the door for cell therapy in solid tumors

03 Jul 2019

In previous years, delegates at the American Society for Clinical Oncology (ASCO) annual meeting had been treated to exciting clinical data from anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapies such as Kymriah (tisagenlecleucel; Novartis), Yescarta (axicabtagene ciloleucel; Gilead), and various pipeline assets in advanced hematologic malignancies.

Topic cancer cell-and-gene-therapy

Trialtrove: 医療用医薬品の臨床試験情報データベース

Geographic Trials Trends: Digging Beneath the Surface

02 Jul 2019

The geographic scope of industry sponsored clinical trial activities has gone global. Successful programs require putting all the pieces together to ensure efficient enrollment of the target patients at high quality facilities to reliably execute detailed study protocols.  Myriad differences between countries, including disease epidemiology, standard of care options, and logistical factors around medical facilities and practices, create challenges to making the right geographic choices.

Topic clinical-trials

A Nautical but Nice Look at BTK inhibitors for Rheumatoid Arthritis

15 Jun 2019

Skipta, the leading social network of specialized online medical communities for verified healthcare professionals, recently hosted a virtual advisory board session, through its proprietary Skipta Gather technology, asking physicians what they saw as the current unmet needs in the treatment of rheumatoid arthritis (RA).

Topic arthritis

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

Immuno-Oncology: Halfway To Adulthood

By Daniel Chancellor 11 Jun 2019

In April, immuno-oncology (IO) celebrated its ninth birthday, following the approval of Provenge, the first drug that harnesses the body’s immune system to fight cancer, in April 2010. Since this landmark event, it has been a tremendous decade for the field, with IO becoming part of the standard-of-care in a range of treatment settings and the Nobel Prize being awarded for the discovery of immune checkpoint inhibition. It is the checkpoint inhibitor drug classes that are leading the IO revolution and will act as a foundation for the next decade of oncology research. This article reviews the childhood years of IO and predicts what the future may hold as it reaches double digits and matures through adolescence.

Topic cancer

Pharma consulting: 医療用医薬品のコンサルティング

Biosimilars commercial best practices in the age of sustainability

By Duncan Emerton 10 Jun 2019

What’s the boggle with biologics? If there is one fact that even the most casual observer of the pharma industry is aware of, it is that biologics are the leading growth engine of global medicines spending. Revenues from biologics increased by 70% during 2011–16 to reach $232bn, accounting for roughly 20–22% of total pharmaceutical spending.

Topic biosimilars

Strategic Transactions

PharmAI industry is smartening up

23 May 2019

PharmAI – industry is smartening up to the potential of artificial intelligence

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

The Dangerous Threat of Burkholderia Cepacia Complex in Cystic Fibrosis Patients

13 May 2019

Cystic fibrosis is an inherited disease characterized by frequent respiratory infections Cystic fibrosis (CF) is an inherited disease affecting water retention, most notably causing patients to produce large amounts of thick mucus. This mucus blocks up the lungs and digestive system and is difficult to clear. People with CF commonly and frequently suffer from respiratory infections, resulting in scarring of their airways.

Trialtrove: 医療用医薬品の臨床試験情報データベース

A Case for Celebrating Parkinson’s Disease

01 May 2019

There’s a song running through my head as I reflect on April being Parkinson’s Disease (PD) Awareness month.  It’s Kool & The Gang’s hit from 1980, Celebration.  In case you don’t recall, it started, “There’s a party goin’ on right here. A celebration to last throughout the years…”, with the refrain, “Come on now…Celebration…Let’s all celebrate and have a good time!”.  Now why, you might ask, would anyone want to celebrate Parkinson’s? You’re right, but it’s not the disease I’m celebrating.  I’m celebrating the people who fight Parkinson’s Disease day in and day out. I’m referring to those who suffer from the disease, their family members, caretakers, and the researchers working for a cure or symptom relief.

Topic parkinsons-disease diseases

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日:9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。